
    
      MGCD265 belongs to a new class of drugs with anticancer potential, known as tyrosine kinase
      inhibitors. MGCD265 was shown to slow down the growth of human cancer cells in mice. Clinical
      studies are being pursued to evaluate the safety of MGCD265 in cancer patients.

      In this study, oral MGCD265 is administered daily on a 7 days on / 7 days off schedule to
      patients with advanced malignancies.
    
  